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I would like to focus attention first on
three major and immediate problem areas
inherent in any testing system and then
to discuss to a limited extent a major prob-
lem, generally not discussed, involved in the
elucidation of the meaningfulness of any
test system for human health and welfare.
The three problem areas I wish to discuss
first are: (1) the toxic agent-the suspect
compound; (2) the target-the tissue likely
to develop the toxic response; and (3) the
time factors involved in test systems.
There are three questions that must be
asked regarding the toxic agent. What chem-
ical is the toxic agent? How much of that
agent is present? How long is that agent
present? These questions must be asked
whether one is doing an experiment on
Neurospora, on human cells in vitro, on
laboratory animals, individually on man, or
on the human population. In more classical
terminology, the question of the identity of
the agent refers to studies on metabolic al-
terations of the compounds by cellular ac-
tivity. The question of amount or concentra-
tion of agent is the function of not only the
metabolism but also the distribution and the
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environmental exposure and absorption
rates. How long the susceptible cells are ex-
posed to the toxic agent is a function of en-
vironmental exposure, distribution, metabol-
ism excretion, and absorption, and these are
all problems which might best be described
as the pharmacological disposition of the
toxic agent.
That the human body or the bacterial
cell has the capability metabolically to alter
foreign organic compounds is well known.
It is, however, becoming increasingly ap-
parent that in the hazardous process of
attempting to extrapolate data for labora-
tory test systems to man, the major impedi-
ment is the different metabolic patterns in
the various species of test organisms andl
man. These differences may be both qualita-
tive in that different chemical metabolites
may be produced and quantitative in that
different rates of production may occur.
The ability of the hepatic microsomal
mixed function oxidase system to alter
a great variety of foreign organic com-
pounds is well known indeed, and I will not
discuss it further in any great detail (1-3).
It may be worthwhile to point out certain
generalizations which apply to this system
in mammals. First, lipid-soluble compounds
are rendered less lipid-soluble and more
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tend to have a more rapid metabolism of
foreign compounds than large animals. Third,
herbivorous animals tend to metabolize
compounds more actively than do carnivor-
ous animals.
It is important to recognize that metabo-
lic alteration of administered compounds
may occur in the gut even before absorption
has occurred. This may vary between species
or within species; variation may even occur
in the same individual at different times and
on different diets. We are all familiar with
the fact that sodium cyclamate becomes the
more toxic cyclohexylamine by action of
bacteria in the gastrointestinal tract. It is
also becoming increasingly apparent that
there are sites of metabolism in the verte-
brate body beyond the liver. The lung, the
testes, the kidney, and other organs may
play important roles in the metabolism of
the administered compound.
The age and the sex of the animals can be
important. These and other physiological
factors can influence the metabolism of
foreign compounds. Factors external to the
animal may also be important. The ability of
one therapeutic drug to affect the metabol-
isrim drastically and therefore alter the toxic-
ity or activity of a second therapeutic drug
is now well known. It seems likely that this
will be demonstrated for environmental
chemicals. Thus, in the design of meaningful
and effective test systems and in the ex-
trapolation of data from these test systems
to man, one must constantly ask whether
the agent being tested is the original com-
pound or one or more metabolites.
The second major concern is how much of
the compound-be it the original agent or a
more toxic metabolite- is in contact with
the target tissue. Here it is necessary to look
at what is described as the pharmacokinet-
ics of a compound. This includes a variety
of factors. The rate of absorption through
the skin, the lungs, or the gastrointestinal
tract is important. It must be recognized that
the hydrogen ion concentration of the stom-
ach can affect the rate and extent of absorp-
tion of partially ionized compounds. For
slowly absorbed compounds, the gastrointes-
tinal tract surface to volume ratio and tran-
sit time can be of considerable importance,
and these vary among species. The route of
administration in the experimental situation
may be important. There is good evidence
that after an intraperitoneal injection al-
most all of the compound flows through the
hepatic system and therefore is susceptible
to metabolism before it reaches the rest of
the body. With a subcutaneous or intraven-
ous injection this is not true, and the first
passage of the compound to the other tis-
sues of the body is in its unaltered state.
The question of how long the toxic agent
stays in contact with susceptible tissue is
also important. There may be delays in
absorption or penetration that lead to pro-
longed, low tissue concentrations. This, of
course, is a function not only of the absorp-
tion and metabolism, but also of two other
major factors. The first is the excretory
rate. Primary routes of excretion are renal
and biliary. It is clear that the small mam-
mals excrete compounds by the renal route
much more rapidly than do large mammals
(4). Biliary -excretion is a complex active
process which has not been well studied in a
comparative way (5). One must take into
consideration not only the immediate bili-
ary excretion but also the potential reabsorp-
tion of the compound from the gastrointes-
tinal tract after it has been excreted.
The distribution rate of the compound
after absorption throughout the body is of
major importance. This is well illustrated
by the following facts: the cardiac output of
the mouse is such that the blood volume is
circulated 20 times per minute, while the
cardiac output of man is such that the
blood volume is circulated once per minute.
Thus, the rate of distribution and mixing
and delivery to the tissues of a compound
within the body of a small mammal is very
much more rapid than that in the body of a
large mammal. Dedrick and co-workers have
developed these principles in an important
series of studies (6).
The concept which follows from these
comparative studies on metabolic alteration,
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with the notion that small mammals dispose
of (i.e., distribute, metabolize, and excrete)
foreign organic compounds at a more rapid
rate than do large mammals. This overall
observation is supported by older empirical
data on the relative toxicity of anticancer
drugs in laboratory mice, rats, hamsters,
dogs, monkeys, and in man. The lethal toxic-
ity, or the maximum tolerated dose in man,
was close to identical to the dose in the
experimental animals if adjusted to a unit
dose per meter surface area or unit dose per
weight to the two-thirds power. This sug-
gests that on a milligram per kilo basis the
mouse is in fact 10 to 12 times more resistant
to an average compound than is man (7).
These considerations are important first
in the in vitro experiments where proper
estimates of concentration and duration
must be made, also in experiments with
laboratory animals, and finally in man, if
one is actually to predict toxicity to man.
The last problem is one of the tissue target
itself. There are really three aspects to this.
The first concerns the problem of barriers
between the general circulation and the
susceptible cell or area within the cell. The
blood-brain barrier is well known; the blood-
testicular barrier has been described by
Dixon (8); other barriers may well exist
within the body. Second is the question of
the innate susceptibility of the cell. For
example, Flamm describes the differences in
repair mechanisms between bacteria in rod-
ents and man (9), which can influence the
apparent innate susceptibility of the tissue
target. Finally, I think it is important to con-
sider the number-the quantity-of the sus-
ceptible cells in the test systems relative to
those in man. This is particularly important
when searching for a rare event. If an agent
induces a mutation rate of 10-6 but there are
only 104 cells available, it would be unlikely
that a mutation would be detected. These
considerations I think deserve much more
attention than they have had in the past.
The last factor related to the toxic agent
that I will discuss is the time-by this I
mean the duration of the exposure. Chemical
mutagenesis tests as currently designed con-
sist of a brief exposure to the test animal or
the test organism of the suspect compound.
Very often, however, the real life situation
is one of either a long-term, low-dose ex-
posure or repeated small or moderate ex-
posures. To what extent these are compar-
able I think is not known.
Another aspect of time is the ability of
the human to accumulate compounds which
are slowly excreted and/or metabolized over
decades of exposure. For instance, in the
mouse 2 ppm of DDT in the diet will yield,
after about 11/2 yr of exposure, a concentra-
tion in the fat of 5 to 6 ppm of DDT and
its metabolites (10). This is about the same
concentration present in the fat of the aver-
age U.S. citizen after decades of exposure
at an exposure rate of about 0.015 to 0.04
ppm in his diet (11).
In the process of comparing in vitro
studies or laboratory animal studies with
man, it is necessary to consider all of the
factors mentioned above: those related to
the toxic agent, those related to the target
tissue, and those related to time. We must
be sure that in all cases we are considering
the same chemical at the same concentration
for the same duration in the test system as
is the case in the human situation. Unfor-
tunately, even with proper and extensive
consideration of these factors, important
problems remain. It would be inadequate to
compare what I call the "median" or aver-
age mouse to the median or average man, or
the median Drosophila to the median man,
or the median Traclescantia to the median
man, or the median Neurospora to the med-
ian man. Our aim is to protect from the
toxic effects of environmental chemicals
more than just the median or the average
man; it is to protect a very large fraction of
the human population. It is beyond the realm
of this discussion to consider what that
proper fraction should be. To put it simply,
to estimate safe levels for human exposure
we must be concerned about human variabil-
ity, about exposure variability, about en-
vironmental variability, and about synergis-
tic variability. Each one of these factors
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centration or exposure in an ideal situation
into an exposure that can cause toxicity.
It is known that for certain lipid-soluble
therapeutic drugs the steady-state plasma
concentration in man can vary by a factor
of 30-fold between individual patients when
the same dose is given to each patient. It is
known that for certain compounds the half-
life plasma in a small population of patients
can vary 10-fold (12). Thus, knowledge of
the average or median rate of drug disposi-
tion for the average man may not give
much information as to the drug disposition
rate of that 5%o or 1%o or 0.1%o of the pop-
ulation that is either "slow" or "fast."
We know there can be a very great vari-
ability in the actual exposure of environ-
mental agents to man. We know that environ-
mental effects themselves can affect meta-
bolism, distribution, and excretion, as well
as response, of foreign compounds, and these
must be taken into consideration. Lastly,
and perhaps most importantly, we must be
particularly aware of the possibility of syn-
ergistic toxic interactions. It is well demon-
strated for therapeutic drugs that one agent
can drastically increase the toxicity of a
second therapeutic agent. While this has
not been well demonstrated for environ-
mental agents, it seems very likely that it
also occurs. Studies on synergistic toxicity
might be ideal for in vitro methodology in
which large numbers of compounds could be
run alone and in combination very easily.
It seems to me that, as we consider our test
systems and the population that we want to
protect, we must be aware of the toxic
agent, the target cell, the time factor, and
the variability factors. We must try very
hard to achieve the same concentrations of
the same chemical for the same time in the
same tissues in the test systems as we do in
man. When we have done that we have not
yet succeeded, because we almost must an-
ticipate the variability intrinsic in man and
his complex way of life.
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